-

Owkin Announces Availability of K Pro in the AWS Marketplace SaaS Category

PARIS--(BUSINESS WIRE)--Owkin, a leading provider of agentic AI solutions for biopharma, today announced the availability of K Pro in the SaaS category of AWS Marketplace. Customers can now use AWS Marketplace to easily discover, buy, and deploy AI agents solutions, including Owkin’s agentic AI co-pilot for biopharma using their AWS accounts, accelerating agent and agentic workflow development.

"By offering K Pro in AWS Marketplace we're providing customers with a streamlined way to access our agentic AI co-pilot, helping them buy and deploy agent solutions faster and more efficiently." - Adi Ravia, Head of Product at Owkin.

Share

K Pro helps organizations make smarter decisions across their discovery and development pipeline by delivering decision-grade, data-driven biological insights, enabling customers to increase clinical success rates and change program trajectories.

"By offering K Pro in AWS Marketplace we're providing customers with a streamlined way to access our agentic AI co-pilot, helping them buy and deploy agent solutions faster and more efficiently." said Adi Ravia, Head of Product at Owkin. "Our customers in biotech, pharmaceuticals and research are already using these capabilities to access and analyse deep multimodal patient data, understand and review the scientific literature and uncover treatment-relevant biomarkers, demonstrating the real-world value of K Pro."

K Pro delivers essential capabilities including natural language interaction, biological reasoning, and proprietary multimodal data access. These features enable customers to unify fragmented workflows into an insight-driven research experience.

With the availability of SaaS in AWS Marketplace, customers can significantly accelerate their procurement process to drive AI innovation, reducing the time needed for vendor evaluations and complex negotiations. With centralized purchasing using AWS accounts, customers maintain visibility and control over licensing, payments, and access through AWS.

To learn more about K Pro in AWS Marketplace, visit https://aws.amazon.com/marketplace/pp/prodview-janhwocmshmxm.

About Owkin: Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Artificial Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is K Pro, an AI copilot and its new LLM finetuned on biology called OwkinZero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

Contacts

To request an interview with Owkin and AWS, please contact aws.france@wpp.com.

Owkin



Contacts

To request an interview with Owkin and AWS, please contact aws.france@wpp.com.

Social Media Profiles
More News From Owkin

Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial ins...

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co...

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the...
Back to Newsroom